Teva will invest in OTC as ‘core asset’ for group
This article was originally published in OTC Bulletin & The Rose Sheet
Teva’s OTC portfolio remains a “core asset” in which the Israeli generics giant will continue to invest, according to chief executive officer Kåre Schultz.
You may also be interested in...
US investigators fan out to non-China inspection priorities and Secretary Azar talks supply management; warning letters hit record keeping, investigations and basic GMP compliance.
Mallinckrodt to pay $1.6bn and place its generics unit in bankruptcy under agreement in principle for US global settlement; six states are not on board, including New York, whose suit is still set to go to trial March 20.